Prediction of exacerbation frequency of AECOPD based on next-generation sequencing and its relationship with imbalance of lung and gut microbiota: a protocol of a prospective cohort study.
Prediction of exacerbation frequency of AECOPD based on next-generation sequencing and its relationship with imbalance of lung and gut microbiota: a protocol of a prospective cohort study.
复制标题
基于下一代测序的AECOPD加重频率的预测及其与肺部和肠道微生物群体失衡的关系：前瞻性队列研究的协议。
DOI：
10.1136/bmjopen-2020-047202
复制
发表时间：
2021-09-02
期刊：
影响因子：
2.9
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Deng L;Yan J;Xu H;Huang C;Lv Y;Wu Q;Xu Y;Chen X
频繁急性加重表型慢性阻塞性肺疾病（AECOPD）患者的住院率高于罕见急性加重表型，疾病进展快，治疗难度更大。目前，尚无法预测COPD频繁急性加重表型的患者。下呼吸道植物群和肠道植物群的组成与AECOPD密切相关，但两者之间的具体关联机制尚不十分清楚。本研究采用宏基因组下一代测序（mNGS）技术，探讨COPD患者肠道和气道的微生物特征，并分析测序结果与炎症因子、免疫因子和营养因子的相关性。这将是一项前瞻性队列研究。我们计划招募152名稳定期COPD患者。在基线时，我们将通过mNGS检测受试者的诱导痰和粪便植物群，以及血液免疫水平的变化，并对患者的病情进行评估。每2个月，我们将通过电话范围检查急性加重的数量。12个月后，我们将再次检查血液免疫水平的变化，评估患者的病情并统计发作次数。本研究已获得广东省中医院伦理委员会批准（批准号：ZF 2019 -219-03）。研究结果将发表在同行评审期刊上。ClinicalTrials.gov注册表（ChiCTR 2000032870）。
Patients with frequent acute exacerbation phenotype chronic obstructive pulmonary disease (AECOPD) have a higher hospitalisation rate than infrequent exacerbation, the disease progresses quickly and treatment is more difficult. At present, it is impossible to predict patients with COPD with frequent acute exacerbation phenotypes. The composition of the lower respiratory tract flora and the intestinal flora is closely related to AECOPD, but the specific association mechanism between them is not very clear. This study used metagenomic next-generation sequencing (mNGS) technology to explore the microbial characteristics of the intestinal tract and airways of patients with COPD, and analyse the correlation between the sequencing results and inflammatory factors, immune factors and nutritional factors. This will be a prospective cohort study. We intend to recruit 152 patients with stable COPD. In the baseline, we will detect the participants’ induced sputum and faecal flora through mNGS, and changes in blood immune levels, and the patient’s condition is evaluated. Every 2 months, we will check the number of acute exacerbation through the phone range. After 12 months, we will check again the changes in the blood immune level, evaluate the patient’s condition and count the number of episodes. This study has been approved by the ethics committee of Guangdong Provincial Hospital of Traditional Chinese Medicine (approval number ZF2019-219-03). The results of the study will be published in peer-reviewed journals. ClinicalTrials.gov Registry (ChiCTR2000032870).
登录
查看更多内容
DOI：
10.1007/5584_2016_165
发表时间：
2018-01-01
期刊：
CLINICAL RESEARCH INVOLVING PULMONARY DISORDERS
影响因子：
--
作者：
Paplinska-Goryca, Magdalena;Nejman-Gryz, Patrycja;Krenke, Rafal
通讯作者：
Krenke, Rafal
DOI：
10.1164/rccm.202009-3533so
发表时间：
2021-01-01
影响因子：
24.7
作者：
Halpin DMG;Criner GJ;Papi A;Singh D;Anzueto A;Martinez FJ;Agusti AA;Vogelmeier CF
通讯作者：
Vogelmeier CF
影响因子：
1.2
作者：
Guiot, Julien;Demarche, Sophie;Moermans, Catherine
通讯作者：
Moermans, Catherine
影响因子：
1.6
作者：
Hu, Yibing;Shi, Qinghuan;Xu, Bin
通讯作者：
Xu, Bin
DOI：
10.1164/rccm.201806-1135oc
发表时间：
2019-05-15
影响因子：
24.7
作者：
Leitao Filho, Fernando Sergio;Alotaibi, Nawaf M.;Sin, Don D.
通讯作者：
Sin, Don D.